<code id='575DA30681'></code><style id='575DA30681'></style>
    • <acronym id='575DA30681'></acronym>
      <center id='575DA30681'><center id='575DA30681'><tfoot id='575DA30681'></tfoot></center><abbr id='575DA30681'><dir id='575DA30681'><tfoot id='575DA30681'></tfoot><noframes id='575DA30681'>

    • <optgroup id='575DA30681'><strike id='575DA30681'><sup id='575DA30681'></sup></strike><code id='575DA30681'></code></optgroup>
        1. <b id='575DA30681'><label id='575DA30681'><select id='575DA30681'><dt id='575DA30681'><span id='575DA30681'></span></dt></select></label></b><u id='575DA30681'></u>
          <i id='575DA30681'><strike id='575DA30681'><tt id='575DA30681'><pre id='575DA30681'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:Wikipedia    - browse:5
          Novo Nordisk Denmark
          LISELOTTE SABROE/AFP/Getty Images

          A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

          In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

          advertisement

          Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time